Insider Selling: Vor Biopharma (NASDAQ:VOR) Major Shareholder Sells $2,549,123.94 in Stock

Vor Biopharma Inc. (NASDAQ:VOR) major shareholder Reprogrammed Interchange Llc sold 75,262 shares of the stock in a transaction dated Wednesday, October 8th. The stock was sold at an average price of $33.87, for a total transaction of $2,549,123.94. Following the transaction, the insider directly owned 1,423,659 shares in the company, valued at $48,219,330.33. This trade represents a 5.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Thursday, October 9th, Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma stock. The shares were sold at an average price of $32.07, for a total value of $1,567,709.88.
• On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The stock was sold at an average price of $33.84, for a total value of $934,796.16.
• On Monday, October 6th, Reprogrammed Interchange Llc sold 70,763 shares of Vor Biopharma stock. The stock was sold at an average price of $37.01, for a total value of $2,618,938.63.
• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The shares were sold at an average price of $37.83, for a total value of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The stock was sold at an average price of $39.83, for a total value of $1,292,523.33.
• On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The stock was sold at an average price of $39.19, for a total value of $54,866.00.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The shares were sold at an average price of $1.54, for a total transaction of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.80, for a total transaction of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The shares were sold at an average price of $32.80, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The shares were sold at an average price of $35.00, for a total transaction of $525,000.00.

Vor Biopharma Stock Down 1.5%

VOR opened at $31.23 on Monday. Vor Biopharma Inc. has a fifty-two week low of $2.62 and a fifty-two week high of $65.80. The firm has a market cap of $214.05 million, a price-to-earnings ratio of -0.11 and a beta of 2.07. The stock has a 50-day simple moving average of $37.73.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts’ consensus estimates of ($11.40) by ($32.20).

Analyst Ratings Changes

A number of equities research analysts recently commented on VOR shares. Zacks Research raised Vor Biopharma from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 10th. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research note on Wednesday, September 24th. Wedbush reissued an “outperform” rating on shares of Vor Biopharma in a research report on Thursday, June 26th. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Vor Biopharma in a report on Thursday, August 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research note on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $113.83.

Institutional Trading of Vor Biopharma

A number of large investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP raised its position in shares of Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after purchasing an additional 25,930 shares during the period. Money Concepts Capital Corp raised its holdings in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after acquiring an additional 26,535 shares during the period. XTX Topco Ltd bought a new stake in Vor Biopharma during the 2nd quarter valued at $66,000. Goldman Sachs Group Inc. lifted its position in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Vor Biopharma in the first quarter worth $100,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.